Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis.

Excess free iron generates oxidative stress that hallmarks diseases of aging. The observation that patients with Alzheimer's disease or Parkinson's disease show a dramatic increase in their brain iron content has opened the possibility that disturbances in brain iron homeostasis may contribute to the pathogenesis of these disorders. While the reason for iron accumulation is unknown, iron localization correlates with the production of reactive oxygen species in those areas of the brain that are prone to neurodegeneration. A role for iron is also proposed in atherosclerosis, a further frequent disorder of aging. We will review experimental evidences for an involvement of iron in these diseases and discuss some mouse models with impairment in iron-related genes that may be useful to study the role of iron in these disorders.

[1]  Peter Riederer,et al.  The relevance of iron in the pathogenesis of Parkinson’s disease , 2011, Journal of neurochemistry.

[2]  M. Wessling-Resnick,et al.  Attenuated Inflammatory Responses in Hemochromatosis Reveal a Role for Iron in the Regulation of Macrophage Cytokine Translation1 , 2008, The Journal of Immunology.

[3]  M. Hentze,et al.  Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. , 2008, Annual review of nutrition.

[4]  E. Nemeth.  Iron regulation and erythropoiesis , 2008, Current opinion in hematology.

[5]  L. Silvestri,et al.  A potential pathogenetic role of iron in Alzheimer's disease , 2008, Journal of cellular and molecular medicine.

[6]  Clara Camaschella,et al.  Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. , 2008, Blood.

[7]  B. Ghetti,et al.  Expression of a Mutant Form of the Ferritin Light Chain Gene Induces Neurodegeneration and Iron Overload in Transgenic Mice , 2008, The Journal of Neuroscience.

[8]  N. A. Georgiou,et al.  Can Iron Chelators Influence the Progression of Atherosclerosis? , 2008, Hemoglobin.

[9]  R. Mahley,et al.  Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease. , 2007, Current Alzheimer research.

[10]  G. Perry,et al.  Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. , 2007, Biochemistry.

[11]  A. Pietrangelo.  Hemochromatosis: An endocrine liver disease , 2007, Hepatology.

[12]  Ya Ke,et al.  Brain iron metabolism: Neurobiology and neurochemistry , 2007, Progress in Neurobiology.

[13]  Elizabeta Nemeth,et al.  Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. , 2007, Blood.

[14]  G. Musci,et al.  Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI‐ceruloplasmin , 2007, The EMBO journal.

[15]  H. Cario,et al.  Recent developments in iron chelation therapy. , 2007, Klinische Padiatrie.

[16]  G. Boysen,et al.  Hereditary hemochromatosis genotypes and risk of ischemic stroke , 2007, Neurology.

[17]  R. Tanzi,et al.  The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element , 2007, Molecular Psychiatry.

[18]  M. Pook,et al.  GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. , 2006, Genomics.

[19]  S. David,et al.  Age-Related Changes in Iron Homeostasis and Cell Death in the Cerebellum of Ceruloplasmin-Deficient Mice , 2006, The Journal of Neuroscience.

[20]  T. Moos,et al.  Ferroportin in the postnatal rat brain: implications for axonal transport and neuronal export of iron. , 2006, Seminars in pediatric neurology.

[21]  Robert B. Wilson.  Iron dysregulation in Friedreich ataxia. , 2006, Seminars in pediatric neurology.

[22]  E. Morgan,et al.  Brain capillary endothelial cells mediate iron transport into the brain by segregating iron from transferrin without the involvement of divalent metal transporter 1 , 2006, Journal of neurochemistry.

[23]  M. Hentze,et al.  Iron homeostasis in the brain: complete iron regulatory protein 2 deficiency without symptomatic neurodegeneration in the mouse , 2006, Nature Genetics.

[24]  J. Connor,et al.  Moderate iron deficiency in infancy: Biology and behavior in young rats , 2006, Behavioural Brain Research.

[25]  D. Stephan,et al.  Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[26]  N. Andrews,et al.  Cybrd1 (duodenal cytochrome b) is not necessary for dietary iron absorption in mice. , 2005, Blood.

[27]  P. Højrup,et al.  Identification of the receptor scavenging hemopexin-heme complexes. , 2005, Blood.

[28]  G. Pinkus,et al.  A mouse model of juvenile hemochromatosis. , 2005, The Journal of clinical investigation.

[29]  K. C. K. Lloyd,et al.  Movement disorders in the Hfe knockout mouse , 2005, Nutritional neuroscience.

[30]  S. You,et al.  Ferritin in atherosclerosis. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[31]  V. Subramaniam,et al.  First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin , 2005, Gut.

[32]  J. Eschbach.  Iron requirements in erythropoietin therapy. , 2005, Best practice & research. Clinical haematology.

[33]  N. Andrews,et al.  Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. , 2005, The Journal of clinical investigation.

[34]  B. Halliwell,et al.  The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. , 2005, Free radical biology & medicine.

[35]  Y. Huang,et al.  Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. , 2005, Metabolism: clinical and experimental.

[36]  A. Donovan,et al.  The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. , 2005, Cell metabolism.

[37]  S. Sindel,et al.  Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. , 2005, International heart journal.

[38]  P. Riederer,et al.  Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man , 2005, Journal of Neural Transmission.

[39]  D. German,et al.  Three-dimensional computer reconstruction of midbrain dopaminergic neuronal populations: From mouse to man , 2005, Journal of Neural Transmission.

[40]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[41]  R. Hawkins,et al.  α‐Synuclein produces a long‐lasting increase in neurotransmitter release , 2004, The EMBO journal.

[42]  E. Rossi,et al.  Clinical penetrance of C282Y homozygous HFE haemochromatosis. , 2004, The Clinical biochemist. Reviews.

[43]  J. Andersen,et al.  Perspectives on MAO-B in aging and neurological disease , 2004, Molecular Neurobiology.

[44]  V. Beneš,et al.  Targeted mutagenesis of the murine IRP1 and IRP2 genes reveals context-dependent RNA processing differences in vivo. , 2004, RNA.

[45]  Alberto Gatti,et al.  The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Paul Henman.  Targeted! , 2004 .

[47]  M. Davies,et al.  Direct Detection and Quantification of Transition Metal Ions in Human Atherosclerotic Plaques: Evidence for the Presence of Elevated Levels of Iron and Copper , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[48]  M. Hentze,et al.  Balancing Acts Molecular Control of Mammalian Iron Metabolism , 2004, Cell.

[49]  H. Chertkow,et al.  Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI , 2004, Neurobiology of Aging.

[50]  A. Smith,et al.  Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease , 2004, Journal of Medical Genetics.

[51]  Z. Sheng,et al.  Expression of the iron transporter ferroportin in synaptic vesicles and the blood–brain barrier , 2004, Brain Research.

[52]  M. Youdim,et al.  Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.

[53]  K. Iwai,et al.  Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis , 2004, The EMBO journal.

[54]  E. Morgan,et al.  The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain , 2003, Journal of neurochemistry.

[55]  Christopher Exley,et al.  Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[56]  A. Mackinnon,et al.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.

[57]  E. Hirsch,et al.  Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease , 2003, Journal of neurochemistry.

[58]  Heather A. O'Neill,et al.  Yeast Frataxin Sequentially Chaperones and Stores Iron by Coupling Protein Assembly with Iron Oxidation* , 2003, Journal of Biological Chemistry.

[59]  S. David,et al.  Glycosylphosphatidylinositol-anchored Ceruloplasmin Is Required for Iron Efflux from Cells in the Central Nervous System* , 2003, Journal of Biological Chemistry.

[60]  A. Bush.  Copper, zinc, and the metallobiology of Alzheimer disease. , 2003, Alzheimer disease and associated disorders.

[61]  T. Montine,et al.  Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[62]  J. Connor,et al.  Iron Deficiency Alters Iron Regulatory Protein and Iron Transport Protein Expression in the Perinatal Rat Brain , 2003, Pediatric Research.

[63]  C. Franceschi,et al.  Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy , 2003, Mechanisms of Ageing and Development.

[64]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[65]  Z. Harris.  Aceruloplasminemia , 2003, Journal of the Neurological Sciences.

[66]  B. Halliwell,et al.  Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. , 2003, Free radical biology & medicine.

[67]  O. Combarros,et al.  Interaction of the H63D Mutation in the Hemochromatosis Gene with the Apolipoprotein E Epsilon 4 Allele Modulates Age at Onset of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[68]  S. Mandel,et al.  Genes and oxidative stress in parkinsonism: cDNA microarray studies. , 2003, Advances in neurology.

[69]  Xudong Huang,et al.  An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.

[70]  G. London,et al.  Iron Therapy, Advanced Oxidation Protein Products, and Carotid Artery Intima-Media Thickness in End-Stage Renal Disease , 2002, Circulation.

[71]  V. Felitti,et al.  Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. , 2002, The American journal of medicine.

[72]  S. Mooney,et al.  The Ferroxidase Activity of Yeast Frataxin* , 2002, The Journal of Biological Chemistry.

[73]  M. Ebadi,et al.  Deferoxamine Attenuates Iron-Induced Oxidative Stress and Prevents Mitochondrial Aggregation and α-Synuclein Translocation in SK-N-SH Cells in Culture , 2002, Developmental Neuroscience.

[74]  E. Hirsch,et al.  Lack of up‐regulation of ferritin is associated with sustained iron regulatory protein‐1 binding activity in the substantia nigra of patients with Parkinson's disease , 2002, Journal of neurochemistry.

[75]  A. Hofman,et al.  Mutations in the Hemochromatosis Gene (HFE) and Stroke , 2002, Stroke.

[76]  Hironobu Naiki,et al.  Iron (III) induces aggregation of hyperphosphorylated τ and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease , 2002 .

[77]  M. Ristow,et al.  The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. , 2002, Human molecular genetics.

[78]  Jean-Pierre Julien,et al.  Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury , 2002, The Journal of Neuroscience.

[79]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[80]  D. Oakes,et al.  Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. , 2002, Blood cells, molecules & diseases.

[81]  J. Connor,et al.  Developmental changes in the expression of iron regulatory proteins and iron transport proteins in the perinatal rat brain , 2002, Journal of neuroscience research.

[82]  C. Angelopoulos,et al.  Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[83]  J. Adamec,et al.  Physical evidence that yeast frataxin is an iron storage protein. , 2002, Biochemistry.

[84]  F. Torti,et al.  Regulation of ferritin genes and protein. , 2002, Blood.

[85]  M. Frasier,et al.  Magnesium Inhibits Spontaneous and Iron-induced Aggregation of α-Synuclein* , 2002, The Journal of Biological Chemistry.

[86]  Alberto Gatti,et al.  The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease , 2002, FEBS letters.

[87]  Hironobu Naiki,et al.  Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. , 2002, Journal of neurochemistry.

[88]  M. Frasier,et al.  Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. , 2002, The Journal of biological chemistry.

[89]  N. Hattori,et al.  Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). , 2001, Parkinsonism & related disorders.

[90]  C. Beaumont,et al.  Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[91]  J. Beard,et al.  Iron deficiency decreases dopamine D1 and D2 receptors in rat brain , 2001, Pharmacology Biochemistry and Behavior.

[92]  C. Morris,et al.  Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.

[93]  G. Annoni,et al.  The hemochromatosis gene affects the age of onset of sporadic Alzheimer’s disease , 2001, Neurobiology of Aging.

[94]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[95]  D. Allsop,et al.  alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. , 2001, Free radical biology & medicine.

[96]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[97]  J. Melki,et al.  Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits , 2001, Nature Genetics.

[98]  Kazuhiro Iwai,et al.  Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice , 2001, Nature Genetics.

[99]  A. Friedman,et al.  The current state of free radicals in Parkinson's disease. Nigral iron as a trigger of oxidative stress. , 2001, Advances in neurology.

[100]  Xudong Huang,et al.  Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. , 2008, Journal of neurochemistry.

[101]  P. Riederer,et al.  Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.

[102]  D. Selkoe,et al.  Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein , 2000, Annals of the New York Academy of Sciences.

[103]  John Hardy,et al.  The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.

[104]  M. Golub,et al.  Chronic marginal iron intakes during early development in mice alter brain iron concentrations and behavior despite postnatal iron supplementation. , 2000, The Journal of nutrition.

[105]  P Bélisle,et al.  Iron stores and coronary artery disease: a clinical application of a method to incorporate measurement error of the exposure in a logistic regression model. , 2000, Journal of clinical epidemiology.

[106]  A. Warren,et al.  Are hereditary hemochromatosis mutations involved in Alzheimer disease? , 2000, American journal of medical genetics.

[107]  M. Arca,et al.  Haemochromatosis gene mutations and risk of coronary artery disease , 2000, European Journal of Human Genetics.

[108]  K. Fischbeck,et al.  Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. , 2000, Human molecular genetics.

[109]  C. Beaumont,et al.  Early Embryonic Lethality of H Ferritin Gene Deletion in Mice* , 2000, The Journal of Biological Chemistry.

[110]  J. Ramires,et al.  C282Y mutation in the HLA-H Gene is Not a Risk Factor for Patients with Myocardial Infarction , 2000, Journal of cardiovascular risk.

[111]  J. Cooper,et al.  Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. , 2000, Human molecular genetics.

[112]  L. Petrucelli,et al.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[113]  G. Perry,et al.  Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.

[114]  E. Beutler,et al.  The effect of transferrin polymorphisms on iron metabolism. , 1999, Blood cells, molecules & diseases.

[115]  E. Masliah,et al.  Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease* , 1999, The Journal of Biological Chemistry.

[116]  K. Jellinger,et al.  Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease? , 1999, Life sciences.

[117]  J. Sixma,et al.  Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. , 1999, Circulation.

[118]  T. Lakka,et al.  Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. , 1999, Circulation.

[119]  J. Gitlin,et al.  Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[120]  F. Foury.  Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain , 1999, FEBS letters.

[121]  A. Hofman,et al.  Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. , 1999, The American journal of clinical nutrition.

[122]  C. Leitão,et al.  Does serum ferritin correlate with coronary angiography findings? , 1999, International journal of cardiology.

[123]  Nancy Andrews,et al.  Transferrin receptor is necessary for development of erythrocytes and the nervous system , 1999, Nature Genetics.

[124]  P D Griffiths,et al.  Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. , 1999, Brain : a journal of neurology.

[125]  E. Masliah,et al.  Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro , 1999 .

[126]  L. Fenart,et al.  Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier* , 1999, The Journal of Biological Chemistry.

[127]  D. Radisky,et al.  The Yeast Frataxin Homologue Mediates Mitochondrial Iron Efflux , 1999, The Journal of Biological Chemistry.

[128]  Gregory J. Anderson,et al.  Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse , 1999, Nature Genetics.

[129]  E. Masliah,et al.  Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. , 1999, Neuroreport.

[130]  J C Rothwell,et al.  Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.

[131]  A. Lang,et al.  New developments in understanding the etiology of Parkinson's disease and in its treatment , 1998, Current Opinion in Neurobiology.

[132]  E. Morgan,et al.  Evidence for low molecular weight, non‐transferrin‐bound iron in rat brain and cerebrospinal fluid , 1998, Journal of neuroscience research.

[133]  S. Murayama,et al.  Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein , 1998, Neurology.

[134]  M. Hentze,et al.  Activation of iron regulatory protein-1 by oxidative stress in vitro. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[135]  R. Hynes,et al.  The combined role of P- and E-selectins in atherosclerosis. , 1998, The Journal of clinical investigation.

[136]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[137]  A. Lin,et al.  Striatal dopamine dynamics are altered following an intranigral infusion of iron in adult rats. , 1998, Free radical biology & medicine.

[138]  W. Sly,et al.  HFE gene knockout produces mouse model of hereditary hemochromatosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[139]  A. Lin,et al.  Neuroprotection by S‐nitrosoglutathione of brain dopamine neurons from oxidative stress , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[140]  P. Jenner,et al.  Oxidative mechanisms in nigral cell death in Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[141]  E. Hirsch,et al.  Iron metabolism and Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[142]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[143]  A. Terashi,et al.  Association of transferrin C2 allele with late-onset Alzheimer’s disease , 1997, Human Genetics.

[144]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[145]  D. Meyers,et al.  Possible association of a reduction in cardiovascular events with blood donation. , 1997, Heart.

[146]  M. Bradbury.  Transport of Iron in the Blood‐Brain‐Cerebrospinal Fluid System , 1997, Journal of neurochemistry.

[147]  M. MacDonald,et al.  Frataxin gene of Friedreich's ataxia is targeted to mitochondria , 1997, Annals of neurology.

[148]  F. Foury,et al.  Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria , 1997, FEBS letters.

[149]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[150]  M. Pandolfo,et al.  Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. , 1997, Science.

[151]  R. Wolff,et al.  The Hemochromatosis Founder Mutation in HLA-H Disrupts β2-Microglobulin Interaction and Cell Surface Expression* , 1997, The Journal of Biological Chemistry.

[152]  P. Libby,et al.  Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. , 1997, The American journal of pathology.

[153]  H. Parving,et al.  Population based study of rates of multiple pregnancies in denmark, 1980-94 , 1997, BMJ.

[154]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[155]  T. Shima,et al.  Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.

[156]  C. Marsden,et al.  Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. , 1997, Journal of neural transmission. Supplementum.

[157]  G. Bartzokis,et al.  MR evaluation of age-related increase of brain iron in young adult and older normal males. , 1997, Magnetic resonance imaging.

[158]  L. Pascazio,et al.  Echo color Doppler imaging of carotid vessels in hemodialysis patients: evidence of high levels of atherosclerotic lesions. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[159]  P. Thong,et al.  Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study , 1996, Brain Research.

[160]  M. Dehouck,et al.  Receptor-Mediated Transcytosis of Transferrin through Blood-Brain Barrier Endothelial Cells , 1996 .

[161]  P. Patel,et al.  Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion , 1996, Science.

[162]  P. Thong,et al.  Elemental changes in atherosclerotic lesions using nuclear microscopy. , 1996, Cellular and molecular biology.

[163]  J. Araujo,et al.  Iron overload augments the development of atherosclerotic lesions in rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[164]  J. Connor,et al.  A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.

[165]  T. Sarna,et al.  The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. , 1995, Biochimica et biophysica acta.

[166]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[167]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[168]  C. Olanow,et al.  Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra , 1994, Experimental Neurology.

[169]  J. Gutteridge.  Hydroxyl Radicals, Iron, Oxidative Stress, and Neurodegeneration a , 1994, Annals of the New York Academy of Sciences.

[170]  R. Rauramaa,et al.  Association of risk factors and body iron status to carotid atherosclerosis in middle-aged eastern Finnish men. , 1994, European heart journal.

[171]  M. Vlad,et al.  Concentration of copper, zinc, chromium, iron and nickel in the abdominal aorta of patients deceased with coronary heart disease. , 1994, Journal of trace elements and electrolytes in health and disease.

[172]  N. Hattori,et al.  Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys , 1994, Neuroscience Letters.

[173]  N. Seidah,et al.  The family of subtilisin/kexin like pro-protein and pro-hormone convertases: divergent or shared functions. , 1994, Biochimie.

[174]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[175]  W. Aronow.  Serum ferritin is not a risk factor for coronary artery disease in men and women aged > or = 62 years. , 1993, The American journal of cardiology.

[176]  D. Williamson,et al.  Iron and ischemic heart disease. , 1993, Circulation.

[177]  H. Macdonald.  High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. , 1993, Circulation.

[178]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[179]  C. Morris,et al.  Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. , 1992, The Biochemical journal.

[180]  O. Aruoma,et al.  Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. , 1992, The Biochemical journal.

[181]  Heikki Korpela,et al.  High Stored Iron Levels Are Associated With Excess Risk of Myocardial Infarction in Eastern Finnish Men , 1992, Circulation.

[182]  C. Barrow,et al.  Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. , 1992, Journal of molecular biology.

[183]  N. Robakis,et al.  Immunohistochemical evidence of antioxidant stress in Alzheimer's disease , 1992 .

[184]  D. Perl,et al.  Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study , 1992, Annals of neurology.

[185]  J. Connor,et al.  Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.

[186]  P. Riederer,et al.  Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease , 1991, Journal of neurochemistry.

[187]  C. Barrow,et al.  Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. , 1991, Science.

[188]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[189]  C. Marsden,et al.  Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.

[190]  M. Delong,et al.  Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.

[191]  A. J. Valente,et al.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[192]  J. de Vellis,et al.  Transferrin gene expression and secretion by rat brain cells in vitro , 1990, Journal of neuroscience research.

[193]  A. Lusis,et al.  Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins , 1990, Nature.

[194]  A J Barkovich,et al.  Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. , 1989, Radiology.

[195]  F. Zemlan,et al.  Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation , 1989, Brain Research.

[196]  Bernstein Se.  Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. , 1987 .

[197]  S. E. Bernstein.  Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. , 1987, The Journal of laboratory and clinical medicine.

[198]  E. Larkin,et al.  Effect of prenatal iron deficiency on myelination in rat pups. , 1986, The American journal of pathology.

[199]  A. Chait,et al.  Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. , 1984, The Journal of clinical investigation.

[200]  J. Sullivan.  IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK , 1981, The Lancet.

[201]  R. Hoeldtke,et al.  Bovine adrenal tyrosine hydroxylase: purification and properties. , 1977, The Journal of biological chemistry.

[202]  T. Nukiwa,et al.  The activation of bovine pineal tryptophan 5‐monooxygenase , 1974, FEBS letters.

[203]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .